BioCentury
ARTICLE | Clinical News

Undisclosed intranasal compound: Phase II started

November 24, 2008 8:00 AM UTC

Serenity began a Phase II trial. The compound was developed using the CPE-215 drug delivery technology from CPEX, which spun out from Bentley Pharmaceuticals Inc. (AMEX:BNT, Exeter, N.H.) earlier thi...